13TiP - Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: methodology of phase 3 randomized t...

Date 20 November 2015
Event ESMO Symposium on Immuno-Oncology 2015
Session Welcome reception and general Poster viewing
Topics Cancer Immunology and Immunotherapy
Head and Neck Cancers
Presenter Kevin Harrington
Citation Annals of Oncology (2015) 26 (suppl_8): 5-14. 10.1093/annonc/mdv514
Authors K. Harrington1, J. Machiels2, S.W. Shin3, E. Cohen4, B. Burtness5, C. Gause6, A. Swift6, R. Swaby6, C. Le Tourneau7
  • 1Targeted Therapy Team, The Institute of Cancer Research, SW7 3RP - London/UK
  • 2Department Of Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels/BE
  • 3Oncology And Hematology, College of Medicine, Korea University, Seoul/KR
  • 4Hematology/oncology, University of California, San Diego Moores Cancer Center, La Jolla/US
  • 5Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven/US
  • 6Medical Oncology, Merck & Co., Inc., Kenilworth/US
  • 7Medical Oncology, Institut Curie, Paris/FR

Abstract

Background

Prognosis for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is poor, with limited treatment options and survival rates following standard-of-care therapies. Pembrolizumab is a humanized IgG4 monoclonal antibody against PD-1 designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. It has demonstrated clinical efficacy by investigator-assessed responses (including confirmed and unconfirmed responses) in a phase 1 study of R/M HNSCC. Additionally, preliminary PD-L1 biomarker data suggest that response rates may be greater in PD-L1–positive patients.

Trial design

KEYNOTE-040 is a global, open-label, phase 3 trial of 600 patients with R/M HNSCC for whom prior platinum therapy has failed. Patients will be randomly assigned (1:1) to pembrolizumab (200 mg Q3W) or investigator's choice standard of care (single-agent methotrexate, docetaxel, or cetuximab). Randomization will be stratified by ECOG PS (0 vs 1), human papillomavirus (HPV) status in oropharyngeal cancer by p16 immunohistochemistry testing (positive vs negative), and centralized PD-L1 status (≥50% positive vs not positive PD-L1). Pembrolizumab will be given for ≤24 months or until disease progression, unacceptable toxicity, or investigator decision. Imaging will occur per RECIST v1.1 at 9 weeks and then every 6 weeks thereafter, and AEs will be assessed by NCI CTCAE, v 4.0. Modified RECIST criteria, which allow for continued treatment after initial radiographic progression until confirmation imaging ≥4 weeks, will be used to account for unique responses seen with immunotherapy. Radiographic responses will be confirmed by independent central review by RECIST v1.1 and modified RECIST and will be analyzed in real time for verification of progressive disease by RECIST v1.1. Survival follow-up will occur every 12 weeks. Primary end points are PFS and OS in all patients and in patients with PD-L1 strong positive expression; secondary end points include PFS and OS in patients with any positive PD-L1 expression, safety and tolerability, TTP, ORR, and DOR.

Clinical trial identification

NCT02252042

Disclosure

J.-P. Machiels: Research Funding: Novartis, Sanofi, and Bayer. Consulting or advisory role: MSD. E. Cohen: Consulting or advisory role: Bayer, Novartis, VentiRx, Merck, BMS, AstraZeneca, and Eisai. Speakers Bureau: Biodesix, Bayer. B. Burtness: Research Funding: Boehringer Ingelheim and Genentech. Expert Testimony: Johnson and Johnson. Consulting or advisory role: VentiRx, Novartis, Genentech, Onyx, and Immunogen. C. Gause: Employee and stock or other ownership: Merck. A. Swift: Employee of Merck. R. Swaby: Employee and stock or other ownership: Merck and GlaxoSmithKline. All other authors have declared no conflicts of interest.